Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Stock Statistics & Valuation Metrics

Xuanzhu Biopharmaceutical Co., Ltd. Class H has a market cap or net worth of HK$8.03B. The enterprise value is HK$8.30B.

Xuanzhu Biopharmaceutical Co., Ltd. Class H has 160,702,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xuanzhu Biopharmaceutical Co., Ltd. Class H’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -56.41%.

The current PE Ratio of Xuanzhu Biopharmaceutical Co., Ltd. Class H is ―. Xuanzhu Biopharmaceutical Co., Ltd. Class H’s PEG ratio is -0.28.

In the last 12 months, Xuanzhu Biopharmaceutical Co., Ltd. Class H had revenue of 32.63M and earned -603.29M in profits. Earnings per share was -1.16.

In the last 12 months, operating cash flow was -70.01M and capital expenditures -2.13K, giving a free cash flow of -70.02M billion.

Xuanzhu Biopharmaceutical Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Xuanzhu Biopharmaceutical Co., Ltd. Class H upcoming earnings date is Mar 30, 2026, Before Open (Confirmed).

Xuanzhu Biopharmaceutical Co., Ltd. Class H as a current ratio of 2.06, with Debt / Equity ratio of 0.15%

In the past 12 months, Xuanzhu Biopharmaceutical Co., Ltd. Class H has paid 6.50K in taxes.

Xuanzhu Biopharmaceutical Co., Ltd. Class H EV to EBITDA ratio is -23.74, with an EV/FCF ratio of -127.80.

Xuanzhu Biopharmaceutical Co., Ltd. Class H has HK$216.62M in cash and marketable securities with HK$1.37M in debt, giving a net cash position of HK$215.26M billion.

Gross margin is -38.61%, with operating margin of -1873.40%, and net profit margin of -1848.97%.

The average price target for Xuanzhu Biopharmaceutical Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―